Used together, the two peptides appear to complement each other
Right now the FDAs official explanation for thymosin alpha-1s place in the Category 2 list is that the safety-related information is inadequate for the agency to sufficiently understand the extent of any safety issues raised by the proposed compounded drug. Thymosin Alpha-1 Up for Review in 2027
Noguchi M, Moriya F, Koga N, Matsueda S, Sasada T, Yamada A, et al
It does not constitute medical, legal, or therapeutic advice and is not intended to suggest personal use, dosing, or human application
Subcutaneous injection Subcutaneous administration involves injecting just beneath the skin, typically into the fatty tissue of the abdomen, thigh, or upper arm
What About Nodules or Lumps